Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial.
Kremsner PG, Mann P, Kroidl A, Leroux-Roels I, Schindler C, Gabor JJ, Schunk M, Leroux-Roels G, Bosch JJ, Fendel R, Kreidenweiss A, Velavan TP, Fotin-Mleczek M, Mueller SO, Quintini G, Schönborn-Kellenberger O, Vahrenhorst D, Verstraeten T, Alves de Mesquita M, Walz L, Wolz OO, Oostvogels L; CV-NCOV-001 Study Group. Kremsner PG, et al. Among authors: walz l. Wien Klin Wochenschr. 2021 Sep;133(17-18):931-941. doi: 10.1007/s00508-021-01922-y. Epub 2021 Aug 10. Wien Klin Wochenschr. 2021. PMID: 34378087 Free PMC article. Clinical Trial.
Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial.
Aldrich C, Leroux-Roels I, Huang KB, Bica MA, Loeliger E, Schoenborn-Kellenberger O, Walz L, Leroux-Roels G, von Sonnenburg F, Oostvogels L. Aldrich C, et al. Among authors: walz l. Vaccine. 2021 Feb 22;39(8):1310-1318. doi: 10.1016/j.vaccine.2020.12.070. Epub 2021 Jan 22. Vaccine. 2021. PMID: 33487468 Free PMC article. Clinical Trial.
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
Kremsner PG, Ahuad Guerrero RA, Arana-Arri E, Aroca Martinez GJ, Bonten M, Chandler R, Corral G, De Block EJL, Ecker L, Gabor JJ, Garcia Lopez CA, Gonzales L, Granados González MA, Gorini N, Grobusch MP, Hrabar AD, Junker H, Kimura A, Lanata CF, Lehmann C, Leroux-Roels I, Mann P, Martinez-Reséndez MF, Ochoa TJ, Poy CA, Reyes Fentanes MJ, Rivera Mejia LM, Ruiz Herrera VV, Sáez-Llorens X, Schönborn-Kellenberger O, Schunk M, Sierra Garcia A, Vergara I, Verstraeten T, Vico M, Oostvogels L; HERALD Study Group. Kremsner PG, et al. Lancet Infect Dis. 2022 Mar;22(3):329-340. doi: 10.1016/S1473-3099(21)00677-0. Epub 2021 Nov 23. Lancet Infect Dis. 2022. PMID: 34826381 Free PMC article. Clinical Trial.
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
IST-3 collaborative group; Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A. IST-3 collaborative group, et al. Lancet. 2012 Jun 23;379(9834):2352-63. doi: 10.1016/S0140-6736(12)60768-5. Epub 2012 May 23. Lancet. 2012. PMID: 22632908 Free PMC article. Clinical Trial.
Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited.
Sandercock P, Lindley R, Wardlaw J, Dennis M, Innes K, Cohen G, Whiteley W, Perry D, Soosay V, Buchanan D, Venables G, Czlonkowska A, Kobayashi A, Berge E, Slot KB, Murray V, Peeters A, Hankey GJ, Matz K, Brainin M, Ricci S, Cantisani TA, Gubitz G, Phillips SJ, Antonio A, Correia M, Lyrer P, Kane I, Lundstrom E; IST-3 collaborative group. Sandercock P, et al. Trials. 2011 Nov 30;12:252. doi: 10.1186/1745-6215-12-252. Trials. 2011. PMID: 22129158 Free PMC article. Clinical Trial.
Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke.
Mair G, von Kummer R, Morris Z, von Heijne A, Bradey N, Cala L, Peeters A, Farrall AJ, Adami A, Potter G, Cohen G, Sandercock PA, Lindley RI, Wardlaw JM; IST-3 Collaborative Group. Mair G, et al. Neurology. 2016 Jan 12;86(2):118-25. doi: 10.1212/WNL.0000000000002236. Epub 2015 Dec 9. Neurology. 2016. PMID: 26658907 Free PMC article. Clinical Trial.
Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity.
Wolz OO, Vahrenhorst D, Quintini G, Lemberg C, Koch SD, Kays SK, Walz L, Kulkarni N, Fehlings M, Wengenmayer P, Heß J, Oostvogels L, Lazzaro S, von Eisenhart-Rothe P, Mann P. Wolz OO, et al. Among authors: walz l. Vaccines (Basel). 2024 Apr 6;12(4):388. doi: 10.3390/vaccines12040388. Vaccines (Basel). 2024. PMID: 38675770 Free PMC article.
N1-methylation of adenosine (m1A) in ND5 mRNA leads to complex I dysfunction in Alzheimer's disease.
Jörg M, Plehn JE, Kristen M, Lander M, Walz L, Lietz C, Wijns J, Pichot F, Rojas-Charry L, Wirtz Martin KM, Ruffini N, Kreim N, Gerber S, Motorin Y, Endres K, Rossmanith W, Methner A, Helm M, Friedland K. Jörg M, et al. Among authors: walz l. Mol Psychiatry. 2024 Jan 29. doi: 10.1038/s41380-024-02421-y. Online ahead of print. Mol Psychiatry. 2024. PMID: 38287100
73 results